Oral bioavailability of phenobarbital: A comparison of a solution in myvacet 9-08, a suspension, and a tablet

Pharmacy World and Science

Volumn 22, Issue 2, 2000, Pages 67-71

  Yska X, Jan Peter ^a   Essink, Guus W G ^a   Bosch, Frank H ^a   Lankhaar, Gert ^b   Van Sorge, Adriaan A ^a  

^a RIJNSTATE HOSPITAL   (Netherlands)

^b PRA International USA   (Netherlands)

Author keywords

Bioequivalence; Myvacet 9 08; Oral bioavailability; Phenobarbital; Suspension

Indexed keywords

ACETIC ACID ESTER; ANTICONVULSIVE AGENT; MYVACET 9 08; PHENOBARBITAL; SOLVENT;

ADULT; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SUSPENSION; TABLET;

ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MIDDLE AGED; PHENOBARBITAL; SAMPLE SIZE; SPECTROPHOTOMETRY, ULTRAVIOLET; SUSPENSIONS; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 0034106950     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008770519585     Document Type: Article

References (12)

1. Constantinides PP. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 1995;12: 1561-72.
2. Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int. J. Pharm. 1994;106: 15-23.
3. Acetic and fatty acid esters of glycerol. In: Toxicological evaluation of some food additives. FAO Nutrition meetings report series No. 53A, Rome, 1974:210-3.
4. Mono- and di-acetylated monoglycerides. In: The United States Pharmacopeia, USP 23 / The National Formulary, NF 18. Rockville MD: The United States Pharmacopeial Convention Inc, 1994:2269-70.
5. Wilensky AJ, Friel PN, Levy RH, Comfort CP, Kaluzny SP. Kinetics of phenobarbital in normal subjects and epileptic patients. Eur. J. Clin. Pharmacol. 1982;23: 87-92.
6. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of onfidence intervals. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992;30, Supp No 1:51-8.
7. In vivo bioequivalence guidances. In: The United States Pharmacopeia, USP 23 / The national Formulary, NF 18. Rockville MD: The United States Pharmacopeial Convention Inc, 1994:1929-32.
8. SAS Institute Inc. SAS/STAT User's guide version 6, fourth edition, volume 2. Cary, NC: SAS Institute Inc., 1989.
9. Hollander M, Wolfe DA. In: Nonparametric statistical methods. New York: John Wiley & Sons, 1973:26-66.
10. Nelson E, Powell JR, Conrad K, Likes K, Byers J, Baker S, et al. Phenobarbital pharmacokinetics and bioavailability in adults. J. Clin. Pharmacol. 1982;22: 141-8.
11. Leucuta SE, Popa Lidia, Ariesan M, Popa Letitia, Pop RD, Kory M, et al. Bioavailability of phenobarbital from different pharmaceutical dosage forms. Pharm. Acta Helv. 1977;52: 261-6.
12. Carey MC. Lipid digestion and absorption, Ann. Rev. Physiol. 1983;45:651-77.